click on circles to display study description...
sofosbuvir (n=27) vs. Interferon plus lopinavir/ritonavir (n=30)
randomized controlled trial
Sofosbuvir
Sofosbuvir 400 mg single dose daily, orally, plus standard of care.
Interferon beta-1a and Lopinavir/Ritonavir
Interferon-beta-1a 12 Mu (44 microgram) on day 1 and then every other day subcutaneously plus Lopinavir/ritonavir (200/50 mg, orally; two tablets twice a day) plus standard of care.
All patients received standard of care: supplemental oxygen, noninvasive or invasive ventilation, use of anticoagulants or antibiotic agents, vasopressor support, renal-replacement therapy, use of Immunomodulatory agents and performing extracorporeal membrane oxygenation (ECMO). The duration of antiviral treatment was determined by the time to clinical recovery in the study population sustained,at least for 72 hours.
COVID 19 hospitalized
Patients between 18-75 with chest computerized tomography (CT) findings suggestive of pulmonary infection by COVID-19 with fever (temperature: ≥36.6 °C armpit or ≥ 37.2 °C oral or ≥37.8 °C rectal), physical finding concluding of respiratory infection (rales/crackles or decreased respiratory sounds plus ego phony or increased tactile fremitus or vocal fremitus) and oxygen Saturation of 93% or lower (at room air) and positive report of RT PCR-COVID-19 RNA by a distinguished national diagnostic laboratory. Patients who required mechanical ventilation were excluded.
Open-label.
Single center, Imam 87 Hossein Medical Center, Tehran, Iran.
Clinical recovery as defined by normal body temperature and normal oxygen saturation, sustained for at least 72 hours within 14 days since the initiation of antiviral therapy.
Preliminary results of the phase II.
powered by vis.js Network
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -
An extraction panel is open